N-[(3R,7R,10R,16S,21aS)-7-benzyl-3-(3-carbamimidamidopropyl)-10-[(4-hydroxyphenyl)methyl]-1,4,5,8,13,17-hexaoxo-1H,2H,3H,4H,5H,6H,7H,8H,9H,10H,13H,14H,15H,16H,17H,19H,20H,21H,21aH-pyrrolo[2,1-j]1,4,8,11,15-pentaazacyclononadecan-16-yl]formamide

• ChemBase编号: 3879
• 分子式: C36H45N9O8
• 平均质量: 731.798
• 单一同位素质量: 731.33910945
• SMILES: NC(=N)NCCC[C@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CNC(=O)/C=C\[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)C1=O)NC=O
• Canonical SMILES: O=CN[C@H]1CNC(=O)/C=C\[C@@H](Cc2ccc(cc2)O)NC(=O)[C@H](NC(=O)C(=O)[C@H](NC(=O)[C@H]2N(C1=O)CCC2)CCCNC(=N)N)Cc1ccccc1
• InChI: InChI=1S/C36H45N9O8/c37-36(38)39-16-4-8-26-31(49)34(52)44-27(19-22-6-2-1-3-7-22)32(50)42-24(18-23-10-13-25(47)14-11-23)12-15-30(48)40-20-28(41-21-46)35(53)45-17-5-9-29(45)33(51)43-26/h1-3,6-7,10-15,21,24,26-29,47H,4-5,8-9,16-20H2,(H,40,48)(H,41,46)(H,42,50)(H,43,51)(H,44,52)(H4,37,38,39)/b15-12-/t24-,26+,27+,28-,29-/m0/s1
• InChIKey: CDWXSPKJKIUEQF-AOLOITIXSA-N

名称和登记号

名称

• IUPAC标准名: N-[(3R,7R,10R,16S,21aS)-7-benzyl-3-(3-carbamimidamidopropyl)-10-[(4-hydroxyphenyl)methyl]-1,4,5,8,13,17-hexaoxo-1H,2H,3H,4H,5H,6H,7H,8H,9H,10H,13H,14H,15H,16H,17H,19H,20H,21H,21aH-pyrrolo[2,1-j]1,4,8,11,15-pentaazacyclononadecan-16-yl]formamide
• IUPAC传统名: @cyclotheonamide A
• 别名: Cyclotheonamide A

登记号

• PubChem SID: 160967315; 46507851
• PubChem CID: 46936939

理论计算性质

JChem

• Acid pKa: 9.498418
• 质子受体: 11
• 质子供体: 9
• LogD (pH = 5.5): -3.2888026
• LogD (pH = 7.4): -3.0119753
• Log P: -1.3554153
• 摩尔折射率: 202.6399 cm^3
• 极化性: 73.4955 Å^3
• 极化表面积: 265.01 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -0.36
• LOG S: -4.21
• 溶解度: 4.53e-02 g/l

详细说明

DrugBank - DB04269

Drug information: experimental